← Signal Board

Viridian Therapeutics Ors Shs financial statements

비리디언 테라퓨틱스NASDAQ:VRDN · Nasdaq · Healthcare · sector #20
$18.34+0.33%
2026-10-08 close

Viridian Therapeutics Ors Shs's published financial data is dated 2026-10-04. 2024 revenue was $0M. 2024 operating profit was −$299M.

Reported results

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 8.99
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
8.99
Beneish M-Score
-2.77

No statistical flag

Sloan accrual
-5.07%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

4/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score4/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -76927%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Revenue qualityWarning

OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-81035.0% → -99018.2%, -17983.2%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-99,018.2%
Interest coverage
-98.2x
Return on equity (ROE)
-40.2%

Operating margin −5pp

Operating loss
Interest coverageBase -98.2x adverse case -98.2x
Return on equity (ROE)Base -40.2% adverse case -45%

Revenue −15%

Interest coverage risk
Interest coverageBase -98.2x adverse case -83.4x
Return on equity (ROE)Base -40.2% adverse case -38.3%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -98.2x adverse case -67x
Return on equity (ROE)Base -40.2% adverse case -45.2%

Interest coverage limit

Already below the limit by 100,026.8pp

Interest coverage limit at an operating margin of 1,008.6%

Interest expense coverage threshold

Viridian Therapeutics Ors Shs notifications

Quantus Signal · live data · not investment advice · Privacy Policy